Treatment of such diseases in adults as: – cryptococcal meningitis; the coccidioidomycosis; – invasive candidiasis; – candidiasis of the mucous membranes, including oropharyngeal candidiasis and esophageal candidiasis, candiduria, chronic candidiasis of the skin and mucous membranes; – chronic atrophic candidiasis (candidiasis caused by the use of dentures) with the inefficiency of local dental hygiene products; – vaginal candidiasis, acute or recurrent, when local therapy is not appropriate; – Candida balanitis when local therapy is not appropriate; – dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal dermatomycosis, multi-colored lichen and Candida infections of the skin, when indicated to use systemic therapy; – dermatophytic onychomycosis, when the use of other drugs is not advisable.
Fluconazol 50 ml Composition
active substance: fluconazole;
100 ml of solution contain fluconazole (in terms of dry 100% substance) 0.2 g;
excipients: sodium chloride, sodium edetate, water for injection.
Fluconazol 50 ml Dosage form
Solution for infusion.
Basic physical and chemical properties: transparent colorless liquid; theoretical osmolarity 315 mosmol / l pH 4.0-7.0.
Fluconazol 50 ml Pharmacotherapeutic group
Antifungal agents for systemic use. Triazole derivatives. ATX code J02A C01.
Mechanism of action. Fluconazole is an antifungal agent of the triazole class. The primary mechanism of its action is the suppression of fungal 14-alpha-lanosterol demethylation, mediated by cytochrome P450 (CYP), which is an integral step in the biosynthesis of fungal ergosterol. The accumulation of 14-alpha-methyl-sterols correlates with the subsequent loss of ergosterol by the membrane of the fungal cell and may be responsible for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.
The use of fluconazole at a dose of 50 mg per day for 28 days does not affect the level of testosterone in the blood plasma in men and the level of endogenous steroids in women of reproductive age. Fluconazole at a dose of 200-400 mg per day does not show a clinically significant effect on the level of endogenous steroids or in response to stimulation of ACTH (ACTH) in healthy male volunteers.
Fluconazole is indicated for the treatment of these fungal infections in adults (see the Pharmacological section):
cryptococcal meningitis (see section “Peculiarities of use”);
coccidioidosis (see section “Peculiarities of use”);
candidiasis of the mucous membranes, including candidiasis of the oropharynx and candidiasis of the esophagus, candiduria, chronic candidiasis of the skin and mucous membranes;
chronic atrophic oral candidiasis (candidiasis caused by the use of dentures) with ineffective oral hygiene or local therapy.
Fluconazole is indicated for the prevention of such diseases in adults:
Hypersensitivity to fluconazole, other azole compounds or to any of the excipients of the drug indicated in the “Composition” section.
Concomitant use of fluconazole and terfenadine in patients who use fluconazole multiple times at doses of 400 mg per day or more (according to the results of a multiple-use interaction study).
Concomitant use of fluconazole and other drugs that lengthen the QT interval and are metabolized by the CYP3A4 enzyme, such as cisapride, astemizole, pimozide, quinidine and erythromycin (see Sections “Interaction with other drugs and other types of interactions” and “Peculiarities of use”)